Lyell Immunopharma (LYEL) Invested Capital (2019 - 2025)
Historic Invested Capital for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $329.1 million.
- Lyell Immunopharma's Invested Capital fell 3798.33% to $329.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.1 million, marking a year-over-year decrease of 3798.33%. This contributed to the annual value of $382.8 million for FY2024, which is 4154.93% down from last year.
- Latest data reveals that Lyell Immunopharma reported Invested Capital of $329.1 million as of Q3 2025, which was down 3798.33% from $298.9 million recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Invested Capital ranged from a high of $1.0 billion in Q2 2021 and a low of -$334.0 million during Q1 2021
- Its 5-year average for Invested Capital is $627.8 million, with a median of $697.6 million in 2023.
- In the last 5 years, Lyell Immunopharma's Invested Capital surged by 52562.13% in 2021 and then tumbled by 4723.35% in 2025.
- Over the past 5 years, Lyell Immunopharma's Invested Capital (Quarter) stood at $929.8 million in 2021, then decreased by 10.38% to $833.3 million in 2022, then fell by 21.4% to $655.0 million in 2023, then plummeted by 41.55% to $382.8 million in 2024, then decreased by 14.03% to $329.1 million in 2025.
- Its Invested Capital was $329.1 million in Q3 2025, compared to $298.9 million in Q2 2025 and $336.5 million in Q1 2025.